

# Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a multicentre study comprising two linked open label phase III randomised controlled trials evaluating the effectiveness and cost effectiveness of different methods of pharmacological prophylaxis for patients with temporary lower limb immobilisation.

<b>Submission date</b> 10/05/2024	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/07/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 12/09/2024	<b>Condition category</b> Injury, Occupational Diseases, Poisoning	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

People have an increased risk of blood clots when they have a leg injury treated with a plaster cast or a splint, which happens to over 70,000 people every year in the UK. Blood clots can cause long term problems in the legs and can also move to the lungs, causing serious illness and occasionally death. Medicines are available to reduce the risk of blood clots, but they can also increase the risk of bleeding. In people at high risk of clots, most hospitals use the recommended daily injections which can be uncomfortable and sometimes difficult to give. Tablets are available that reduce the risk of blood clots in other groups, but we don't know if tablets work as well as the injections for people with a leg injury. We also don't know whether people at low risk of blood clots may benefit from any medication.

Our study has two aims - to determine whether giving tablets to people at high risk of clots after a leg injury is as good as injections, and whether giving any medication is better than standard care (advice only) for people at low risk of clots. TiLLI is two linked studies designed to answer these aims.

### Who can participate?

Patients aged 16 years or older, placed in temporary lower limb immobilisation (rigid cast or brace) as a result of an injury that occurred within the last 7 days.

What does the study involve?

Participants will be invited who have been placed in a plaster cast or splint after injury and are being assessed for clot risk. People who agree and are at high risk of clots will have either tablets or injections to reduce their risk; those at low risk will receive tablets, injections, or no medication. Patients and doctors will know what medication they are taking. All patients will be provided with written guidance on the signs and symptoms of blood clots and advice on managing their medication.

What are the possible benefits and risks of participating?

Benefits:

Not provided at time of registration

Risks:

TiLLI-Low: the standard of care for participants considered to be low risk for VTE receive no pharmacological prophylaxis. In TiLLI-Low, participants may be randomised to receive routine care (no prophylaxis), Direct Oral AntiCoagulant (DOAC), or Low Molecular Weight Heparin (LMWH). Administration of anticoagulants may induce a propensity for increased bleeding, which may lead to several complications, including: haematuria, melena or haematochezia, pronounced ecchymosis, prolonged episodes of epistaxis, gingival bleeding, haematemesis or haemoptysis, menorrhagia. Major bleeding events and clinically-relevant bleeding events will be monitored throughout the study.

Within the LMWH cohort requiring self-injection, risks such as cutaneous ecchymosis or irritation at the injection site.

TiLLI-high: the standard of care for participants considered to be high risk for VTE is pharmacological prophylaxis in the form of LMWH. In TiLLI-high, participants will be randomised to receive either routine care (LMWH) or DOAC. Use of DOACs are contraindicated in pregnancy and breast feeding, as such we will exclude participants who are pregnant, actively seeking pregnancy, or breast feeding from the study.

Where is the study run from?

Queen Mary University of London (UK)

When is the study starting and how long is it expected to run for?

May 2024 to April 2028

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

tilli-bjh@qmul.ac.uk

Dr Xavier Griffin, x.griffin@qmul.ac.uk

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr - TiLLI study team

**Contact details**

Queen Mary University of London, Mile End Road  
London  
United Kingdom  
E1 4UJ  
+44 20 7882 5555  
tilli-bjh@qmul.ac.uk

**Type(s)**

Principal Investigator

**Contact name**

Prof Xavier Griffin

**Contact details**

4 Newark Street  
London  
United Kingdom  
E1 2AT  
+44 7983829494  
x.griffin@qmul.ac.uk

**Type(s)**

Principal Investigator

**Contact name**

Prof Daniel Horner

**Contact details**

Northern Care Alliance NHS Foundation Trust, Salford Royal, Stott Lane  
Salford  
United Kingdom  
M6 8HD  
-  
Daniel.horner@srft.nhs.uk

**Additional identifiers****EudraCT/CTIS number**

Nil known

**IRAS number**

1009305

**ClinicalTrials.gov number**

NCT06370273

**Secondary identifying numbers**

V1.0-26/04/24, IRAS 1009305, CPMS 62644

# Study information

## Scientific Title

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a multicentre study comprising two linked open label phase III randomised controlled trials evaluating the effectiveness and cost effectiveness of different methods of pharmacological prophylaxis for patients with temporary lower limb immobilisation.

## Acronym

TiLLI

## Study objectives

Primary objective:

To estimate and draw inferences on the difference in a composite outcome of net clinical benefit, including symptomatic VTE events (any deep vein thrombosis or pulmonary embolism), major bleeding or cause-specific mortality (death from either pulmonary embolus or major bleeding) between treatment groups within 90 days of randomisation.

Secondary objectives:

1. To compare all individual components of the primary composite outcome between treatment groups within 42 and 90 days from randomisation
2. To estimate and draw inferences on the difference in complications (including clinically relevant non-major bleeding and surgical site bleeding) between treatment groups within 42 days from randomisation
3. To report adherence to each therapy
4. To estimate and draw inferences on the acceptability of different prophylactic anticoagulants using the Anti Clot Treatment Scale (ACTS)
5. To estimate and draw inferences on differences in quality-of-life measures, including quality of life-adjusted survival, between treatment groups, up to 90 days post randomisation
6. To estimate and draw inferences on the difference in hospital readmission/reattendance and medication use (specific to VTE and bleeding) between treatment groups within the first 90 days
7. To estimate the health and social care resource use and costs and the relative cost effectiveness between arms
8. To estimate longer term outcomes, such as post thrombotic syndrome, chronic thromboembolic pulmonary hypertension and bleeding complications and draw inferences on cost effectiveness, by using a previously developed decision analytic model, informed by directly measured events up to 90 days

## Ethics approval required

Ethics approval required

## Ethics approval(s)

Approved 22/07/2024, North West – Liverpool Central Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8340; liverpoolcentral.rec@hra.nhs.uk), ref: 24/NW/0166

## Study design

Interventional randomized parallel-group controlled trial

## Primary study design

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Safety, Efficacy

**Participant information sheet****Health condition(s) or problem(s) studied**

Venous thromboembolism (VTE) in population with temporary lower limb immobilisation following injury

**Interventions**

TiLLI study consists of 2 linked randomised controlled trials: TiLLI-High and TiLLI-Low. Participants suitability for TiLLI-High and TiLLI-Low will be established during screening, participants will be randomised using Sealed Envelope. Participants in TiLLI-High will be allocated to either parenteral drug treatment (a) or oral drug treatment (b). Participants in TiLLI-Low will be allocated to treatment (a) or (b), or no drug prophylaxis (c). Site teams are permitted to choose which IMP within the treatment group to use. Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier).

**a) Parenteral drug treatment**

- Enoxaparin 40mg once daily via subcutaneous injection
- Tinzaparin 4500 IU once daily via subcutaneous injection
- Dalteparin 5000 IU once daily via subcutaneous injection
- Fondaparinux 2.5mg once daily via subcutaneous injection

**b) Oral drug treatment**

- Rivaroxaban 10mg OD via oral ingestion
- Apixaban 2.5mg BD via oral ingestion

**c) No drug prophylaxis (TiLLI-Low only)****Intervention Type**

Drug

**Pharmaceutical study type(s)**

Pharmacoeconomic, Prophylaxis, Therapy

**Phase**

Phase III

**Drug/device/biological/vaccine name(s)**

Rivaroxaban, apixaban, enoxaparin sodium, tinzaparin sodium, dalteparin sodium, fondaparinux sodium

**Primary outcome measure**

A composite primary outcome of net clinical benefit, comprising symptomatic VTE events (any deep vein thrombosis or pulmonary embolism), major bleeding or cause-specific mortality (death

from either pulmonary embolus or major bleeding) within 90 days used as a binary variable ('1' if any event occurred, '0' if none of the events occurred).

### **Secondary outcome measures**

1. All individual components of the composite outcome as binary variables ('1' if any event occurred, '0' if no event occurred) of an event happening within 42 days of randomisation for a) major bleeding events and within 90 days for b) symptomatic pulmonary embolism or symptomatic deep vein thrombosis and c) cause-specific mortality
2. Patient satisfaction regarding the burdens and benefits of anticoagulation, using the validated Anti-Clot Treatment Scale (ACTS) for patients allocated to drug treatments, measured 42 days after randomisation
3. Health utility (EQ-5D-5L): differences in EQ-5D-5L QoL utility at 7 days, 42 days and 90 days after randomisation compared to a retrospective baseline and QALYs within 90 days of randomisation
4. Medication adherence: monitor participant adherence to allocated anti-coagulant verified through a digital response system, measured at 7 days, 14 days, 21 days, 28 days, 35 days, and 42 days after randomisation
5. Complications including clinically relevant non-major bleeding and surgical site bleeding, objectively defined by ISTH criteria, reported throughout up until 42 days after randomisation
6. Hospital readmission/reattendance using bespoke Case report forms and review of EHR, research staff to collect information on resources required to deliver subsequent care reviews (including scheduled clinic and unscheduled hospital attendance), and investigations within the first 90 days after randomisation
7. Health and social care resource use, using bespoke Case Report Forms and review of EHR, research staff to collect information on health and social care resource use within the first 90 days after randomisation
8. Patient longer-term outcome VTE and bleeding data, using an existing VTE model with risk-adjusted, population-specific effect estimates from this study, informed by directly measured events up to 90 days after randomisation

### **Overall study start date**

08/05/2024

### **Completion date**

30/04/2028

## **Eligibility**

### **Key inclusion criteria**

1. Age  $\geq 16$  years
2. Placed in temporary lower limb immobilisation (rigid cast or brace) as a result of an injury that occurred within the last 7 calendar days

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Lower age limit**

16 Years

**Sex**

Both

**Target number of participants**

10,044

**Key exclusion criteria**

1. Hospital admission is required direct from the emergency department, minor injuries unit, or fracture clinic setting with an expected length of stay >2 calendar days.
2. Absolute contraindication or known hypersensitivity to anticoagulants, including history of end stage renal failure (eGFR <20ml/min/1.73m<sup>2</sup>), hepatic failure or use of concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole), HIV protease inhibitors (e.g. ritonavir) or active substances strongly inhibiting elimination pathways such as CYP3A4 or P-gp (such as clarithromycin, erythromycin or dronaderone) or a history of heparin induced thrombocytopenia.
3. Pregnancy, actively seeking conception, or active breastfeeding.
4. Preceding use of anticoagulant treatment for >3 calendar days at prophylactic or therapeutic dose
5. Previous enrolment in the TiLLI study.
6. Non-rigid immobilisation (crepe bandage, tubigrip support, strapping).
7. Time since prescription of rigid immobilisation >3 calendar days.
8. Co-enrolment onto a CTIMP where an anticoagulant is administered.
9. People lacking the capacity to consent.
10. Inability or refusal to use acceptable contraception up until after the last administration of IMP. Only applicable for women of childbearing potential who have been randomised to receive apixaban or rivaroxaban

**Date of first enrolment**

01/10/2024

**Date of final enrolment**

31/01/2028

**Locations****Countries of recruitment**

England

Scotland

United Kingdom

Wales

**Study participating centre**

**The Royal London Hospital**

The Royal London Hospital

Alexandra House

London  
United Kingdom  
E1 1BB

**Study participating centre**  
**Newham University Hospital NHS Trust**  
Newham General Hospital  
Glen Road  
London  
United Kingdom  
E13 8SL

**Study participating centre**  
**Epsom Hospital**  
Epsom General Hospital  
Dorking Road  
Epsom  
United Kingdom  
KT18 7EG

**Study participating centre**  
**St Helier Hospital**  
Wrythe Lane  
Carshalton  
United Kingdom  
SM5 1AA

**Study participating centre**  
**Castle Hill Hospital**  
Castle Road  
Cottingham  
United Kingdom  
HU16 5JQ

**Study participating centre**  
**Hull Royal Infirmary**  
Anlaby Road  
Hull  
United Kingdom  
HU3 2JZ



**Study participating centre**  
**Kings College Hospital**  
Mapother House  
De Crespigny Park  
Denmark Hill  
London  
United Kingdom  
SE5 8AB

**Study participating centre**  
**Leeds General Infirmary**  
Great George Street  
Leeds  
United Kingdom  
LS1 3EX

**Study participating centre**  
**Manchester Royal Infirmary**  
Cobbett House  
Oxford Road  
Manchester  
United Kingdom  
M13 9WL

**Study participating centre**  
**Wythenshawe Hospital**  
Southmoor Road  
Wythenshawe  
Manchester  
United Kingdom  
M23 9LT

**Study participating centre**  
**Aberdeen Royal Infirmary**  
Foresterhill Road  
Aberdeen  
United Kingdom  
AB25 2ZN

**Study participating centre**  
**Royal Alexandra Hospital**  
Marine Drive  
Rhyl  
United Kingdom  
LL18 3AS

**Study participating centre**  
**Queen Elizabeth University Hospital**  
1345 Govan Road  
Glasgow  
United Kingdom  
G51 4TF

**Study participating centre**  
**Royal Infirmary of Edinburgh**  
51 Little France Crescent  
Old Dalkeith Road  
Edinburgh  
Lothian  
United Kingdom  
EH16 4SA

**Study participating centre**  
**Southmead Hospital**  
Southmead Road  
Westbury-on-trym  
Bristol  
United Kingdom  
BS10 5NB

**Study participating centre**  
**Salford Care Organisation**  
Northern Care Alliance NHS Foundation Trust  
Salford Royal  
Stott Lane  
Salford  
United Kingdom  
M6 8HD

**Study participating centre**

**John Radcliffe Hospital**

Headley Way  
Headington  
Oxford  
United Kingdom  
OX3 9DU

**Study participating centre****Horton General Hospital**

Trust Unit Offices  
Oxford Road  
Banbury  
United Kingdom  
OX16 9AL

**Study participating centre****Nuffield Orthopaedic Centre**

Windmill Road  
Headington  
Oxford  
United Kingdom  
OX3 7HE

**Study participating centre****Uclh**

250 Euston Road  
London  
United Kingdom  
NW1 2PQ

**Sponsor information****Organisation**

Queen Mary University of London

**Sponsor details**

58 Turner Street  
London  
United Kingdom

E1 2AB  
+44 207 882 7260  
research.governance@qmul.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.qmul.ac.uk/>

**ROR**

<https://ror.org/026zzn846>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

National Institute for Health and Care Research

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## **Results and Publications**

**Publication and dissemination plan**

Peer reviewed scientific journals

Internal report

Conference presentation

Publication on website

Submission to regulatory authorities

No participant identifiable data will be included in publications. All study data will be linked to study ID alone.

**Intention to publish date**

30/04/2029

**Individual participant data (IPD) sharing plan**

Data will be collected in the OpenClinica4 study database and extracted to the BCC Data Safe Haven (DSH). The BCC DSH is accessible upon request to individuals with a proven and approved requirement for access (i.e., study statistician, study health economist). Raw data will not be made publicly accessible. Study data will be pseudo-anonymised using unique participant ID's, it is prohibited to attempt to identify participants from the participant ID. Participant consent will be in place for collecting study data.

**IPD sharing plan summary**

Not expected to be made available